Atrion (NASDAQ:ATRI) Sees Strong Trading Volume

Atrion Co. (NASDAQ:ATRI) shares saw an uptick in trading volume on Wednesday . 13,511 shares traded hands during trading, a decline of 18% from the previous session’s volume of 16,444 shares.The stock last traded at $410.50 and had previously closed at $409.13.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Atrion from a “sell” rating to a “hold” rating in a research report on Friday, March 1st.

Atrion Price Performance

The business’s 50-day moving average price is $400.65 and its two-hundred day moving average price is $365.24. The firm has a market cap of $678.83 million, a price-to-earnings ratio of 34.97 and a beta of 0.60.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings data on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. The business had revenue of $43.58 million during the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%.

Atrion Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 15th were given a $2.20 dividend. This represents a $8.80 dividend on an annualized basis and a dividend yield of 2.28%. The ex-dividend date of this dividend was Thursday, March 14th. Atrion’s dividend payout ratio is presently 79.78%.

Hedge Funds Weigh In On Atrion

Several institutional investors and hedge funds have recently bought and sold shares of ATRI. Kayne Anderson Rudnick Investment Management LLC increased its position in Atrion by 7.7% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 205,297 shares of the medical instruments supplier’s stock worth $128,908,000 after purchasing an additional 14,684 shares during the last quarter. Penn Mutual Asset Management LLC acquired a new position in Atrion during the fourth quarter worth approximately $1,949,000. Citizens Financial Group Inc. RI acquired a new position in Atrion during the fourth quarter worth approximately $1,114,000. Barclays PLC increased its position in Atrion by 356.3% during the fourth quarter. Barclays PLC now owns 2,336 shares of the medical instruments supplier’s stock worth $885,000 after purchasing an additional 1,824 shares during the last quarter. Finally, Royal Bank of Canada increased its position in Atrion by 499.4% during the fourth quarter. Royal Bank of Canada now owns 2,056 shares of the medical instruments supplier’s stock worth $779,000 after purchasing an additional 1,713 shares during the last quarter. Institutional investors and hedge funds own 66.19% of the company’s stock.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.